Alpha Cognition (ACOG) investor relations material

Executive summary

• Achieved 40% sequential revenue growth in Q1 2026, with net product revenue reaching $3.5 million and cumulative revenue of $10.3 million over four quarters since ZUNVEYL launch.

• Strong acceleration in prescriber adoption, nursing home penetration, and payer engagement, with 75% of prescribers and 81% of facilities showing repeat utilization.

• Expanded commercial team to 60 customer-facing representatives and strengthened board governance with new appointments.

• Advanced three real-world clinical studies, accelerated BEACON study timeline, and initiated CONVERGE and RESOLVE studies.

• Strengthened intellectual property with two new patents, extending protection through 2045 and targeting a $14 billion TBI market.

Financial highlights

• Q1 2026 net product revenues reached $3.5 million, up from $2.5 million in Q4 2025 and $2.93 million in Q1 2025; product sales rose to $3.50 million, licensing revenue fell to $29,977.

• Operating expenses for Q1 2026 were $11.6 million, up from $10.7 million in Q4 2025 and $6.3 million in Q1 2025; full-year 2026 guidance reiterated at $54–$58 million.

• Net loss for Q1 2026 was $6.5 million ($0.30 per share basic, $0.32 diluted), compared to $1.7 million ($0.11 per share) in Q1 2025.

• Cash and cash equivalents stood at $54.2 million as of March 31, 2026, down from $66.0 million at year-end 2025; current liabilities: $5.43 million.

Outlook and guidance

• On track to achieve operating profitability in 2027, supported by current cash reserves.

• Full-year 2026 operating expense guidance maintained at $54–$58 million; Q2 spending expected to increase modestly as clinical studies ramp up.

• Expects two real-world evidence datasets by end of 2026 and two strategic product approvals in Asia via partner CMS Pharma.

• No revenue guidance provided for 2026.